Evaluating gut microbiome in patients with POEMS syndrome and other plasma cell disorders

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the characteristics and role of the gut microbiome in patients with POEMS syndrome and other plasma cell disorders, such as AL amyloidosis. Researchers will analyze stool samples from newly diagnosed POEMS patients and compare them with samples from patients with other plasma cell disorders and healthy controls. The study will also examine differences in gut microbiome signatures between active disease and remission in POEMS patients. The goal is to enhance understanding of the relationship between gut microbiome and these rare disorders.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosed with POEMS syndrome (newly diagnosed or in remission) or with newly diagnosed multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS), amyloid light chain (AL) amyloidosis or healthy controls from their households

Exclusion Criteria:

* Age under 18 years
* Pregnancy
* Substance abuse
* Antibiotics use or gastrointestinal endoscopy in the 3 months prior to the study participation
* Chronic gastrointestinal disorder
* Gastrointestinal surgeries in the past 2 years
* Chemotherapy (including anti-plasma cell treatment and steroids) or radiation treatment for cancer within the last 2 years or active cancer (other than plasma cell disorder)

Where it's running

• Mayo Clinic in Rochester
  Rochester, Minnesota, United States Recruiting

Study contacts

• Principal investigator: Angela Dispenzieri, M.D. — Mayo Clinic in Rochester
• Study coordinator: Laura Hawkins
• Email: hawkins.laura@mayo.edu
• Phone: 507-538-1308

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GPRC5D-targeted PET/CT imaging in plasma cell disorders

  This study tests a new GPRC5D-targeted PET/CT imaging method in adults with plasma cell disorders to see if it detects disease better or differently than standard imaging.

  Recruiting Phase 1 Peking University First Hospital · Beijing, Beijing Municipality · NCT07660939

• Radiation plus BCMA/CD3 bispecific antibody (CM336) for solitary bone plasmacytoma with mild marrow involvement

  This will test whether adding the BCMA/CD3 bispecific antibody CM336 after radiotherapy can clear remaining cancer cells and lower the chance of progression in adults with solitary bone plasmacytoma and small amounts of bone marrow involvement.

  Recruiting Phase 2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin · NCT07115667

• Identifying precancerous multiple myeloma in African American adults

  This study is testing a way to find early signs of multiple myeloma in Black and African American adults aged 30 and older to help catch it sooner and improve their health outcomes.

  Recruiting Wake Forest University Health Sciences · Charlotte, North Carolina · NCT06644625

• Quadruplet induction plus autologous transplant followed by teclistamab maintenance for plasma cell leukemia

  This phase 2 trial tests whether adding teclistamab as consolidation after autologous stem cell transplant improves overall survival for patients with plasma cell leukemia compared with the standard D-KRd consolidation.

  Recruiting at 11 sites Phase 2 National Cancer Institute (NCI) · La Jolla, California and 10 other locations · NCT07605416

• Autologous stem‑cell transplant plus BCMA CAR‑T for ultra‑high‑risk multiple myeloma

  This test combines an autologous stem‑cell transplant with BCMA CAR‑T therapy to see if it helps adults (18–70) with ultra‑high‑risk multiple myeloma who are eligible for transplant.

  Recruiting Phase 1/2 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT07109323

• CT0596 CAR-T treatment for plasma cell leukemia

  The study will try CT0596 CAR‑T cell therapy in adults with plasma cell leukemia to see if it is safe and can shrink the disease.

  Recruiting Early Phase 1 Institute of Hematology & Blood Diseases Hospital, China · Tianjin, Tianjin Municipality · NCT06988059

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.